Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: Mechanism of action and effect on cytokine secretion

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 3, 2010, Pages 416-423

  Moutzouris, John P ^a   Che, Wenchi ^a   Ramsay, Emma E ^a   Manetsch, Melanie ^a   Alkhouri, Hatem ^a   Bjorkman, Anna M ^a   Schuster, Friederike ^a   Ge, Qi ^b   Ammit, Alaina J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Faculty of Medicine   (Australia)

Author keywords

I B ; MAPK; MG 132; MKP 1; NF B

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEASOME; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY; ARTICLE; ASTHMA; BRONCHUS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; UPREGULATION; WESTERN BLOTTING;

ASTHMA; CYSTEINE PROTEINASE INHIBITORS; CYTOKINES; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LEUPEPTINS; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, SMOOTH MUSCLE; PROTEASOME ENDOPEPTIDASE COMPLEX; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77249153089     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.12.007     Document Type: Article

References (35)

1. Pelaia G., Cuda G., Vatrella A., Gallelli L., Caraglia M., Marra M., Abbruzzese A., Caputi M., Maselli R., Costanzo F.S., and Marsico S.A. Mitogen-activated protein kinases and asthma. J. Cell Physiol. 202 (2005) 642-653
2. Duan W., and Wong W.S. Targeting mitogen-activated protein kinases for asthma. Curr. Drug Targets 7 (2006) 691-698
3. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
4. Jeffrey K.L., Camps M., Rommel C., and Mackay C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 6 (2007) 391-403
5. Quante T., Ng Y.C., Ramsay E.E., Henness S., Allen J.C., Parmentier J., Ge Q., and Ammit A.J. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am. J. Respir. Cell Mol. Biol. 39 (2008) 208-217
6. Burgess J.K., Lee J.H., Ge Q., Ramsay E.E., Poniris M.H., Parmentier J., Roth M., Johnson P.R., Hunt N.H., Black J.L., and Ammit A.J. Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma. J. Cell. Physiol. 216 (2008) 673-679
7. Issa R., Xie S., Khorasani N., Sukkar M., Adcock I.M., Lee K.Y., and Chung K.F. Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J. Immunol. 178 (2007) 7366-7375
8. Kaur M., Chivers J.E., Giembycz M.A., and Newton R. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol. Pharmacol. 73 (2008) 203-214
9. Sun H., Charles C.H., Lau L.F., and Tonks N.K. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75 (1993) 487-493
10. Kuwano Y., and Gorospe M. Protecting the stress response, guarding the MKP-1 mRNA. Cell Cycle 7 (2008) 2640-2642
11. Lin Y.W., Chuang S.M., and Yang J.L. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J. Biol. Chem. 278 (2003) 21534-21541
12. Price D.M., Terriff D.L., Chik C.L., and Ho A.K. The role of protein turnover in regulating MKP-1 levels in rat pinealocytes. Mol. Cell. Endocrinol. 263 (2007) 134-141
13. Elliott P.J., Zollner T.M., and Boehncke W.H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 81 (2003) 235-245
14. Shah I.M., and Di Napoli M. The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases. Cardiovasc. Hematol. Disord. Drug Targets 7 (2007) 250-273
15. Bennett M.K., and Kirk C.J. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr. Opin. Drug Discov. Devel. 11 (2008) 616-625
16. 2-adrenergic receptor agonists and cAMP arrest human cultured airway smooth muscle cells in the G1 phase of the cell cycle: role of proteasome degradation of cyclin D1. Mol. Pharmacol. 56 (1999) 1079-1086
17. Ip W.K., Wong C.K., Wang C.B., Tian Y.P., and Lam C.W. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor induce adhesion and chemotaxis of human eosinophils via p38 mitogen-activated protein kinase and nuclear factor kappaB. Immunopharmacol. Immunotoxicol. 27 (2005) 371-393
18. Elliott P.J., Pien C.S., McCormack T.A., Chapman I.D., and Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol. 104 (1999) 294-300
19. Adenuga D., Yao H., March T.H., Seagrave J., and Rahman I. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 40 (2009) 464-473
20. Johnson P.R., Armour C.L., Carey D., and Black J.L. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am. J. Physiol. 269 (1995) L514-L519
21. Henness S., van Thoor E., Ge Q., Armour C.L., Hughes J.M., and Ammit A.J. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am. J. Physiol. 290 (2006) L1283-L1290
22. Singer C.A., Baker K.J., McCaffrey A., AuCoin D.P., Dechert M.A., and Gerthoffer W.T. p38 MAPK and NF-kappaB mediate COX-2 expression in human airway myocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 285 (2003) L1087-L1098
23. Nakayama K., Furusu A., Xu Q., Konta T., and Kitamura M. Unexpected transcriptional induction of monocyte chemoattractant protein 1 by proteasome inhibition: involvement of the c-Jun N-terminal kinase-activator protein 1 pathway. J. Immunol. 167 (2001) 1145-1150
24. Brondello J.M., Brunet A., Pouyssegur J., and McKenzie F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 272 (1997) 1368-1376
25. Amrani Y., Ammit A.J., and Panettieri Jr. R.A. Tumor necrosis factor receptor (TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced interleukin-6 and RANTES in human airway smooth muscle cells: role of p38 and p42/44 mitogen-activated protein kinases. Mol. Pharmacol. 60 (2001) 646-655
26. Ammit A.J., Lazaar A.L., Irani C., O'Neill G.M., Gordon N.D., Amrani Y., Penn R.B., and Panettieri Jr. R.A. TNFα-induced secretion of RANTES and IL-6 from human airway smooth muscle cells: modulation by glucocorticoids and β-agonists. Am. J. Respir. Cell Mol. Biol. 26 (2002) 465-474
27. Baraldo S., Faffe D.S., Moore P.E., Whitehead T., McKenna M., Silverman E.S., Panettieri Jr. R.A., and Shore S.A. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L1093-L1102
28. Oltmanns U., Issa R., Sukkar M.B., John M., and Chung K.F. Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br. J. Pharmacol. 139 (2003) 1228-1234
29. Wang X., and Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell. Signal. 19 (2007) 1372-1382
30. Brondello J.M., Pouyssegur J., and McKenzie F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286 (1999) 2514-2517
31. Sohaskey M.L., and Ferrell Jr. J.E. Activation of p42 mitogen-activated protein kinase (MAPK), but not c-Jun NH(2)-terminal kinase, induces phosphorylation and stabilization of MAPK phosphatase XCL100 in Xenopus oocytes. Mol. Biol. Cell 13 (2002) 454-468
32. Chung K.F., and Barnes P.J. Cytokines in asthma. Thorax 54 (1999) 825-857
33. Damera G., Tliba O., and Panettieri Jr. R.A. Airway smooth muscle as an immunomodulatory cell. Pulm. Pharmacol. Ther. 22 (2009) 353-359
34. Brightling C.E., Ammit A.J., Kaur D., Black J.L., Wardlaw A.J., Hughes J.M., and Bradding P. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 171 (2005) 1103-1108
35. Wuyts W.A., Vanaudenaerde B.M., Dupont L.J., Demedts M.G., and Verleden G.M. Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-kappaB in IL-1beta-induced chemokine release in human airway smooth muscle cells. Respir. Med. 97 (2003) 811-817